METHOD FOR TREATMENT OF PATIENTS WITH CHRONIC KIDNEY DISEASE C3-C5 AT DIALYSIS STAGE, EXCLUDING PYELONEPHRITIS, UROLITHIASIS Russian patent published in 2018 - IPC A61K35/66 A61P13/12 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, specifically to nephrology, and can be used to treat patients with chronic kidney disease (CKD) C3-C5 at the pre-dialysis stage, preventing pyelonephritis and urolithiasis. To this end, against the background of drug therapy, which includes ACE inhibitors and / or angiotensin receptor blockers, statins, anti-aggregants, drugs, influencing calcium-phosphorus metabolism and keto-analogues of essential amino acids, a Laminolact synbiotic is additionally administered 5 lozenges 2 times a day during meals. Duration of administering Laminolact at C3a is 4 weeks, at C3b – 8 weeks, at C4 – 16 weeks, C5 without dialysis therapy – 24 weeks.

EFFECT: method improves efficiency of treatment of C3-C5 CKD patients at the pre-dialysis stage by reducing azotemia and normalising the glomerular filtration rate (GFR) while maintaining a stable treatment outcome in the long-term period.

1 cl, 3 tbl, 5 ex